Accéder au contenu
Merck

Comparative proteomic analysis of paclitaxel resistance-related proteins in human breast cancer cell lines.

Oncology letters (2017-01-27)
Hiroya Fujioka, Akiko Sakai, Satoru Tanaka, Kosei Kimura, Akiko Miyamoto, Mitsuhiko Iwamoto, Kazuhisa Uchiyama
RÉSUMÉ

Paclitaxel is widely used to treat various cancers; however, resistance to this drug is a major obstacle to breast cancer chemotherapy. To identify the proteins involved in paclitaxel resistance, the present study compared the proteomes of MCF-7 human breast cancer cells and its paclitaxel-resistant subclone MCF-7/PTX. Using two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionization time of flight mass spectrometry, 11 upregulated and 12 downregulated proteins were identified in MCF-7/PTX cells compared with the parental cell line. These 23 proteins were functionally classified as stress-induced chaperones, metabolic enzymes and cytoskeletal proteins. The anti-apoptotic proteins, stress-70 protein, 78-kD glucose-regulated protein, peptidyl-prolyl

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
MISSION® esiRNA, targeting human PPIA